MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Organovo Holdings Interest Expense 2011-2026 | ONVO
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 6 K | 1.54 M | - | -12 K | - | - | 1 K | 13 K | - | 1.09 M | 2.07 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.07 M | -12 K | 671 K |
Quarterly Interest Expense Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25 K | 25 K | - | - | - | - | - | 1.19 M | 1.45 M | 267 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3 K | - | - | - | - | 13 K | - | 13 K | 13 K | 65 K | - | 203 | 1 K | 1.09 M | - | 182 K | 58.8 K | 53.1 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.45 M | 203 | 278 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
81 M | $ 110.28 | -2.82 % | $ 33.5 B |  USA |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Sotera Health Company
SHC
|
8.55 M | $ 13.21 | -2.44 % | $ 3.75 B | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
|
Biodesix
BDSX
|
8.26 M | $ 14.31 | -2.02 % | $ 1.86 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 16.41 | -11.3 % | $ 177 M |  China |
 |
BioNano Genomics
BNGO
|
5.9 M | $ 1.15 | -0.43 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
-1.45 M | $ 9.03 | -2.48 % | $ 602 M | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
177 M | $ 62.84 | -4.93 % | $ 24.5 B | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Fulgent Genetics
FLGT
|
561 K | $ 15.54 | -5.13 % | $ 470 M | USA |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Guardant Health
GH
|
-10.5 M | $ 84.0 | -4.65 % | $ 10.5 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 24.0 | -2.83 % | $ 667 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 158.89 | -3.78 % | $ 7.88 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 195.64 | -1.27 % | $ 21.7 B | USA |
 |
OpGen
OPGN
|
7.56 K | - | -16.95 % | $ 1.54 M | USA |
 |
DarioHealth Corp.
DRIO
|
-1.93 M | $ 8.45 | - | $ 33.7 M | Israel |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 102.3 | -0.76 % | $ 8.44 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 561.97 | -1.98 % | $ 45.2 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 117.62 | -5.45 % | $ 18.7 B | USA |
 |
PerkinElmer
PKI
|
-3.36 M | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 452.91 | -2.94 % | $ 13.1 B | USA |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 233.1 | -2.91 % | $ 25.4 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.38 | -5.19 % | $ 406 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 4.26 | -7.19 % | $ 2.29 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 7.35 | -5.28 % | $ 942 M | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 164.54 | -2.87 % | $ 28.3 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
National Research Corporation
NRC
|
-95 K | $ 17.2 | -0.95 % | $ 385 M | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
Natera
NTRA
|
9.32 M | $ 184.45 | -5.96 % | $ 18.2 B | USA |
 |
OPKO Health
OPK
|
207 M | $ 1.15 | -1.79 % | $ 798 M | USA |